Status:
COMPLETED
Plasma Exchange for Amanita Toxin-induced Acute Liver Failure
Lead Sponsor:
Hannover Medical School
Conditions:
Acute Liver Failure
Eligibility:
All Genders
Up to 100 years
Brief Summary
Retrospective evaluation of the value of additive therapeutic plasma exchange (PEX) compared to standard medical therapy (SMT) in Amanita toxin-associated acute liver failure in children and adolescen...
Detailed Description
Amanita toxin-associated acute liver failure is a life-threatening condition that can often lead to the need for an emergency liver transplantation. The disease may also be fatal, particularly in pati...
Eligibility Criteria
Inclusion
- Acute liver failure (presence of hepatic encephalopathy of grade I or higher and a coagulopathy with an INR \> 1.5)
- Amanita Toxin related acute liver failure
Exclusion
- Acute liver failure of other reason than Amanita Toxin
- Amanita Toxin associated Hepatitis or severe hepatitis without fulfilling the criteria of acute liver failure
Key Trial Info
Start Date :
January 1 2024
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 10 2025
Estimated Enrollment :
111 Patients enrolled
Trial Details
Trial ID
NCT06187220
Start Date
January 1 2024
End Date
March 10 2025
Last Update
March 12 2025
Active Locations (6)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospital Aachen (RWTH)
Aachen, Germany
2
Hannover Medical School
Hanover, Germany
3
ASST Ospedale Papa Giovanni XXIII
Bergamo, Italy
4
INCMNSZ
Mexico City, Mexico